ALLEGAN, Mich., April 12, 2011 /PRNewswire/ — Perrigo (Nasdaq:
PRGO; TASE) today announced that the Detroit Office of the Food
and Drug Administration (FDA) has concluded its re-inspection of
Perrigo’s Allegan facility. The FDA has informed Perrigo that,
effective immediately, the Company has an acceptable regulatory
status, such that any pending export license and ANDA applications
from this facility will once again be eligible for review and
approval.
Perrigo’s Chairman and CEO Joseph C. Papa stated, “On behalf of
Perrigo, I want to thank the FDA Detroit District for making the
re-inspection of our facilities a priority and for working
cooperatively with us to resolve the issues previously raised in
the Warning Letter. We are convinced that this process has made us
a better company by enhancing the quality of our affordable
healthcare products for our customers.”
Perrigo Company is a leading global healthcare supplier that
develops, manufactures and distributes OTC and generic prescription
(Rx) pharmaceuticals, infant formulas, nutritional products, active
pharmaceutical ingredients (API) and pharmaceutical and medical
diagnostic products. The Company is the world’s largest store brand
manufacturer of OTC pharmaceutical products and infant formulas.
The Company’s primary markets and locations of manufacturing and
logistics operations are the United States, Israel, Mexico, the
United Kingdom and Australia. Visit Perrigo on the Internet (http://www.perrigo.com).
Note: Certain statements in this press release are
forward-looking statements within the meaning of Section 21E of the
Securities Exchange Act of 1934, as amended, and are subject to the
safe harbor created thereby. These statements relate to future
events or the Company’s future financial performance and involve
known and unknown risks, uncertainties and ot
‘/>”/>
